.png)
.svg)
The FDA provides several guidance documents for Chemistry, Manufacturing, and Controls (CMC) submissions, including:
- CMC post approval for manufacturing changes for specified biological products to be documented in annual reports: This guidance details the types of changes that can be included in annual reports for specified biological products.
- Comparability Protocols for Post-Approval Changes to Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA: This guidance provides recommendations on developing comparability protocols to support post-approval changes.
- Changes to Disposable Manufacturing Materials: Questions and Answers: This guidance addresses questions related to changes in disposable manufacturing materials.
- Drug Products, Including Biological Products, that Contain Nanomaterials: This guidance provides recommendations for developing drug products containing nanomaterials.
- Current Good Manufacturing Practice Requirements for Combination Products: This guided draft outlines the current good manufacturing practice requirements for combination products.
Key Considerations for CMC Submissions
- Quality System Regulation (QSR): Ensuring compliance with QSR requirements (21 CFR 820) for medical devices and combination products.
- Good Manufacturing Practice (GMP): Following GMP guidelines for drugs and biologics (21 CFR 210 and 211).
- Risk-Based Approach: Implementing a risk-based approach to identify and mitigate potential quality issues.
- Documentation and Record-Keeping: Maintaining accurate and detailed documentation and records of manufacturing processes, testing, and quality control.
For more information, visit https://eemedicals.com/
.svg)
.svg)
.svg)